Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.39 USD | +1.70% | -16.72% | -69.20% |
Mar. 05 | MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement | MT |
Feb. 13 | MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split | MT |
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 45.39M |
---|---|---|---|---|---|
Net income 2021 | -29M | Net income 2022 | -15M | EV / Sales 2021 | - |
Net cash position 2021 | 11.41M | Net cash position 2022 | 4.69M | EV / Sales 2022 | - |
P/E ratio 2021 |
-7.1
x | P/E ratio 2022 |
-2.94
x | Employees | 10 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 3.15% |
1 day | +1.70% | ||
1 week | -16.72% | ||
Current month | -30.32% | ||
1 month | -26.46% | ||
3 months | -67.84% | ||
6 months | -85.41% | ||
Current year | -69.20% |
Managers | Title | Age | Since |
---|---|---|---|
Ian Rhodes
DFI | Director of Finance/CFO | 51 | 21-04-14 |
President | 71 | 20-10-31 | |
Adam Kaplin
CTO | Chief Tech/Sci/R&D Officer | 57 | 20-12-17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 58 | 17-08-07 | |
President | 71 | 20-10-31 | |
Joshua Silverman
CHM | Chairman | 54 | 18-09-05 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.39 | +1.70% | 32,983 |
24-03-27 | 2.35 | +1.73% | 10,308 |
24-03-26 | 2.31 | -6.10% | 36,768 |
24-03-25 | 2.46 | -7.17% | 37,787 |
24-03-22 | 2.65 | -7.67% | 41,563 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-69.20% | 4.92M | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |